What is it about?
We followed 68 healthy adults for six months after a third mRNA COVID-19 vaccine dose. IgG and IgA antibody levels remained elevated, while small short-term changes appeared in inflammatory markers, clotting tests and lymphocyte counts. No clinical adverse events following immunisation were observed among participants.
Featured Image
Photo by Fusion Medical Animation on Unsplash
Why is it important?
Longer-term monitoring helps clarify both booster effectiveness and safety. The sustained antibody response supports booster immunogenicity, while the modest laboratory changes provide context for continued surveillance in larger and more diverse populations.
Perspectives
From my perspective, this work matters because Longer-term monitoring helps clarify both booster effectiveness and safety. I hope the findings support further research and informed, evidence-based decisions.
Yasar Yousafzai
Khyber Medical University
Read the Original
This page is a summary of: Immune and hematologicak responses to the third dose of an mRNA COVID-19 vaccine: a six-month longitudinal study, Frontiers in Cellular and Infection Microbiology, July 2025, Frontiers,
DOI: 10.3389/fcimb.2025.1615227.
You can read the full text:
Contributors
The following have contributed to this page
